Li, Xiuqing W. Choi, Wesley Yan, Rui Yu, Haiyang Krasnoperov, Valery Ram Kumar, S. Schuckman, Anne J. Klumpp, David Pan, Chong-Xian Quinn, David S. Gill, Inderbir Gill, Parkash S. Liu, Ren <i>In vivo</i> efficacy of sEphB4-HSA combined with Bevacizumab. <p>A, 5637 tumors were treated with sEphB4-HSA alone (20 mg/kg, 3 times a week), Bevacizamab alone (20 mg/kg, 3 times a week), or sEphB4-HSA combined with Bevacizamab. PBS was used as control. Data are presented as mean ± standard deviation. Student <i>t</i>-test (2 tails, unpaired) was used to calculate P value: *, P<0.05; **, P<0.01. B, tumors harvested from the xenograft study were lysed for EphB4 immunoprecipitation, followed by immunoblotting using EphB4 and phopho-tyrosine antibodies. sEphB4-HSA treatment significantly reduced EphB4 tyrosine phosphorylation <i>in vivo</i>.</p> Transitional Cell Carcinoma;EphB 4 expression;bladder tumor xenograft;survival factor;tumor cell lines;24 cases;EphB 4 signal strength;EphB 2;EphB 4;EphB 4 Receptor Kinases;cis;tyrosine kinase activity;TCC specimens show loss 2014-08-22
    https://plos.figshare.com/articles/figure/_In_vivo_efficacy_of_sEphB4_HSA_combined_with_Bevacizumab_/1149461
10.1371/journal.pone.0105326.g003